Ideal: A 28-week open-label extension of a 24-week double-blind study of the first transdermal patch in Alzheimer's disease

被引：0
|
作者：
Froelich, L. [1 ]
Barone, P. [2 ]
Foerstl, H. [3 ]
Onofrj, M. [4 ]
Nagel, J.
Ros, J. [5 ]
Tekin, S. [6 ]
Orgogozo, J. [7 ]
机构：
[1] Univ Heidelberg, Cent Inst Mental Hlth, D-6800 Mannheim, Germany
[2] Univ Naples Federico 2, Naples, Italy
[3] Tech Univ Munich, D-8000 Munich, Germany
[4] Gabriele DAnnunzio Univ Fdn, Chieti, Italy
[5] Novartis Pharma AG, Basel, Switzerland
[6] Novartis Pharmaceut Corp, E Hanover, NJ USA
[7] CHU Pellegrin, Bordeaux, France
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2007年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：48 / 49
页数：2
相关论文
共 50 条
  • [31] LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY
    Ketter, Terence A.
    Sarma, Kaushik
    Silva, Robert
    Kroger, Hans
    Cucchiaro, Josephine
    Loebel, Antony
    DEPRESSION AND ANXIETY, 2016, 33 (05) : 424 - 434
  • [32] A 28-Week, Randomized, Double-Blind Study of Olanzapine Versus Aripiprazole in the Treatment of Schizophrenia
    Kane, John M.
    Osuntokun, Olawale
    Kryzhanovskaya, Ludmila A.
    Xu, Wen
    Stauffer, Virginia L.
    Watson, Susan B.
    Breier, Alan
    JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (04) : 572 - 581
  • [33] Safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in Japan
    Matsumoto, Hideo
    Ishigooka, Jun
    Ono, Hiroaki
    Tadori, Yoshihiro
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2018, 72 (09) : 701 - 712
  • [34] Lurasidone in bipolar I depression: a 24 week, open-label extension study
    Ketter, T.
    Pikalov, A.
    Sarma, K.
    Silva, R.
    Kroger, H.
    Cucchiaro, J.
    Loebel, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S443 - S444
  • [35] Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study
    Song, I-H
    Heldmann, F.
    Rudwaleit, M.
    Haibel, H.
    Weiss, A.
    Braun, J.
    Sieper, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) : 1108 - 1110
  • [36] A naturalistic, 24-week, open-label, add-on study of vortioxetine in bipolar depression
    Siwek, Marcin
    Chrobak, Adrian Andrzej
    Soltys, Zbigniew
    Dudek, Dominika
    Krupa, Anna Julia
    Rybakowski, Janusz Kazimierz
    PSYCHIATRIA POLSKA, 2022, 56 (03) : 509 - 522
  • [37] Lurasidone in Bipolar I Depression: A 24 Week, Open-label Extension Study
    Ketter, Terence
    Sarma, Kaushik
    Silva, Robert
    Xu, Jane
    Cucchiaro, Josephine
    Loebel, Antony
    NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S534 - S535
  • [38] Lurasidone in bipolar I depression: a 24 week, open-label extension study
    Ketter, T. A.
    Sarma, K.
    Silva, R.
    Kroger, H.
    Cucchiaro, J.
    Loebel, A.
    Grossman, F.
    Pikalov, A.
    BIPOLAR DISORDERS, 2014, 16 : 131 - 131
  • [39] A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease
    Articus, K.
    Baier, M.
    Tracik, F.
    Kuehn, F.
    Preuss, U. W.
    Kurz, A.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (07) : 790 - 796
  • [40] Comment on "Efficacy and safety of a transdermal donepezil patch in patients with mild-to-moderate Alzheimer's disease: A 24-week, randomized, multicenter, double-blind, parallel-group, non-inferiority study"
    Mutlay, Feyza
    Kaya, Derya
    Isik, Ahmet Turan
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2023, 23 (07) : 582 - 583
12345